- Report
- December 2023
- 152 Pages
Global
From €5682EUR$5,950USD£4,752GBP
- Report
- December 2023
- 80 Pages
United States
From €5682EUR$5,950USD£4,752GBP
- Report
- January 2024
- 150 Pages
Global
From €4632EUR$4,850USD£3,873GBP
- Report
- November 2021
- 40 Pages
China
From €2483EUR$2,600USD£2,076GBP
- Report
- July 2021
- 50 Pages
China
From €2483EUR$2,600USD£2,076GBP
From €2483EUR$2,600USD£2,076GBP
- Report
- June 2021
- 50 Pages
China
From €2483EUR$2,600USD£2,076GBP
- Report
- May 2021
- 50 Pages
China
From €2483EUR$2,600USD£2,076GBP
- Report
- November 2023
- 250 Pages
Global
From €4775EUR$5,000USD£3,993GBP
- Report
- July 2023
- 78 Pages
United States
From €3343EUR$3,500USD£2,795GBP
- Report
- March 2024
- 150 Pages
Global
From €4250EUR$4,450USD£3,554GBP
- Report
- December 2023
- 150 Pages
Global
From €4250EUR$4,450USD£3,554GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4727EUR$4,950USD£3,953GBP
- Report
- November 2023
- 432 Pages
Global
From €9073EUR$9,500USD£7,587GBP
- Report
- November 2023
- 230 Pages
Global
From €7163EUR$7,500USD£5,990GBP
- Report
- July 2022
- 100 Pages
Global
From €2626EUR$2,750USD£2,196GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- January 2022
- 160 Pages
Global
From €9073EUR$9,500USD£7,587GBP

The Prostate Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it can vary depending on the stage and severity of the disease. Common treatments include hormone therapy, chemotherapy, and radiation therapy.
The Prostate Cancer Drugs market is highly competitive, with many companies vying for market share. Major players in the market include Astellas Pharma, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are constantly researching and developing new drugs to treat prostate cancer, as well as improving existing treatments. Show Less Read more